Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT From Elan

16-Mar-2010 - Azur Pharma Limited announced it has signed a definitive agreement with Elan Pharmaceuticals, Inc. (a subsidiary of Elan Corporation, plc) to acquire the analgesic therapy, PRIALT(R) (ziconotide intrathecal infusion). PRIALT is indicated in the United States for the management of severe chronic ...

Graffinity and Elan launch fragment-based drug discovery collaboration

27-Jan-2009 - Graffinity Pharmaceuticals GmbH announced that it has entered into a research collaboration with Elan Pharmaceuticals, Inc., a subsidiary of Elan Corporation, plc. Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of novel ...

Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103)

22-Oct-2008 - Elan Corporation, plc and Transition Therapeutics Inc. announced the achievement of the patient enrollment target for a Phase 2 clinical study of ELND005 (AZD-103) in patients with Alzheimer's disease. The study is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy ...

Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI in Oncology

08-Sep-2008 - Elan Corporation, plc and Biogen Idec announced the initiation of the first clinical trial of TYSABRI® (natalizumab) in oncology. The first dose of TYSABRI was administered in the trial. The objectives of this Phase I/II study are to evaluate the safety and potential anti-tumor activity of ...

Transition Therapeutics Announces Completion of Phase I Clinical Studies with Alzheimer's Disease Drug Candidate

31-Aug-2007 - Transition Therapeutics Inc. announced the completion of Phase I clinical studies with Alzheimer's disease drug candidate ELND-005/AZD-103. Transition and its development partner Elan Corporation, plc. have performed multiple Phase I studies evaluating the safety, tolerability and pharmacokinetic ...

TYSABRI Demonstrates Significant Health-Related Quality-of-Life Improvements for Multiple Sclerosis Patients

22-Aug-2007 - Biogen Idec and Elan Corporation, plc announced the publication of results demonstrating that patients treated with TYSABRI(R) (natalizumab) showed a significant improvement in health-related quality-of-life (HRQoL) measures when compared to placebo. These results are from the first Phase III ...

FDA Grants Fast Track Designation to Alzheimer's Disease Drug Candidate AZD-103/ELND005

10-Apr-2007 - Transition Therapeutics Inc. announced that the United States Food and Drug Administration has granted Fast Track designation to investigational drug candidate AZD-103/ELND005, being developed in collaboration with Elan Corporation, plc. for the treatment of Alzheimer's disease. AZD-103/ELND005 ...

Elan and Transition Therapeutics Inc. Announce Global Collaboration to Develop and Commercialize Alzheimer's Disease Drug AZD-10

04-Oct-2006 - Elan Corporation, plc and Transition Therapeutics Inc. announced an exclusive, worldwide collaboration agreement for the joint development and commercialization of a novel therapeutic agent, AZD-103, for the treatment of Alzheimer's disease. AZD-103 is a small molecule compound in Phase I ...

Biogen Idec and Elan reintroduce TYSABR for the Treatment of Relapsing Forms of Multiple Sclerosis

25-Jul-2006 - Biogen Idec and Elan Corporation, plc announced the commercial availability of TYSABRI(R) (natalizumab) for the treatment of relapsing forms of multiple sclerosis (MS) in the U.S. As previously announced, the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License ...

Elan and Biogen Idec Announce TYSABRI® Safety Evaluation Findings in Crohn's Disease and Rheumatoid Arthritis Patients

TYSABRI Safety Evaluation Complete: No New Confirmed Cases of PML

19-Oct-2005 - Elan Corporation, plc and Biogen Idec announced that findings from their safety evaluation of TYSABRI® (natalizumab) in patients with Crohn's disease (CD) and rheumatoid arthritis (RA) resulted in no new confirmed cases of progressive multifocal leukoencephalopathy (PML). The companies have ...